NanoCon Newswire
July 6, 2006 (Berlin) — MagForce Nanotechnologies AG and Siemens Medical Solutions of Siemens AG are to bundle together their competences in the fight against cancer, as revealed by a declaration of intent signed by both companies. The central point of the strategic cooperation is the joint development of the MagForce therapy systems — a key element of MagForce’s nano-cancer therapy — and collaboration in the production and distribution of the systems.
The strategic cooperation of the two companies is the result of several talks and an in-depth examination in which shared goals were identified and the procedure coordinated. The agreement focuses on medical technology and medical technology systems used by MagForce Nanotechnologies in its nano-cancer therapy. These include the therapy system MFH®300F with which first treatment of patients was possible.
In the nano-cancer therapy, tumors are treated locally and weakened by applying heat. Nanoparticles made of iron-oxide are injected into the diseased tissue. Thanks to a covering of the iron oxide particles some 15 nanometers in core diameter, the tumor can be penetrated without problem. Afterwards, a magnetic field is then produced using the therapy system MFH®300F which brings the iron oxide particles into motion. As a result of these oscillations, it is possible to heat up the tumor. This technique allows targeting of almost every part of the human body with millimeter precision and maximum tumor-cell specificity at temperatures ranging from 43-46°C (hyperthermia) to 47-70°C thermoablation). The diseased cell is irreparably weakened as a result of this heat application.
“The collaboration with Siemens Medical Solutions will create entirely new perspectives for us. The declaration of intent and cooperation agreed here serve to confirm once again the results of our research work”, claims CEO of MagForce Nanotechnologies, Dr. Andreas Jordan. “As we are able to draw on Siemens’ experience and contacts, we will gain much time and can thus dedicate ourselves more closely to the development of our nanoparticles.”
MagForce is researching into and currently working intensively on the efficacy study for glioblastomas — i.e. brain tumors. This study is in the second phase and was started at the beginning of 2005. Prior to this, the first phase of the study had been successfully completed. Further studies on other tumor types, such as prostate or also breast cancer, are either already open or still in the planning phase.
About MagForce Nanotechnologies: MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnologybased cancer therapy. Its patented therapy allows the targeted destruction of tumors using magnetic nanoparticles. MagForce’s nanotechnology represents a revolutionary approach to the future successful treatment of solid tumors. For more information, please visit: http://www.magforce.com
Contact: MagForce Nanotechnologies AG, Spandauer Damm 130, 14050 Berlin, Germany Tel. +49 (0) 30 3083800; Fax. +49 (0) 30 30838099 Email: [email protected] URL: http://www.magforce.com